Our take
IpsiHand is one of the few FDA-cleared noninvasive BCI therapies for chronic stroke arm recovery, which sets Kandu apart from generic rehab vendors.1
The Neurolutions and Kandu Health merger combines a device with telehealth services, so buyers evaluate both therapy hardware and care programs.2
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Kandu and what it's for
Stroke survivors and clinicians seeking at-home BCI therapy for upper-limb recovery.1
Health systems and payers managing post-stroke readmissions and rehab outcomes.2
History
Neurolutions was founded in 2007 around BCI technology co-invented with Washington University researchers. In April 2025 it merged with Kandu Health to form Kandu, Inc., with a concurrent $30 million financing.2
Dr. Leo Petrossian, formerly Neurolutions CEO, is CEO of Kandu. Kirsten Carroll, formerly Kandu Health CEO, became general manager.4,2
IpsiHand and stroke recovery
IpsiHand is an FDA-cleared noninvasive BCI system that helps chronic stroke patients regain arm and hand function at home. The company cites more than 8 million therapy repetitions and clinical results including average Fugl-Meyer gains.1
Kandu pairs the device with remote multidisciplinary stroke support through licensed clinicians and an app.2,3
Pricing
Kandu and Neurolutions do not publish consumer list prices for IpsiHand. Access runs through clinical qualification and reimbursement pathways, including a CMS code Neurolutions previously announced.1,2
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Kandu wins or loses |
|---|---|---|---|---|
| Kandu | IpsiHand FDA-cleared noninvasive BCI therapy1 | Merged with Kandu Health in April 2025; $30M financing2 | Clinical claims include Fugl-Meyer gains and millions of therapy reps1 | FDA-cleared noninvasive BCI for chronic stroke arm recovery |
| Myomo | MyoPro powered arm and hand brace15 | Medicare fee schedule rates of $33,481 and $65,8727 | Patients reached through clinician referrals and orthotics and prosthetics channels8,16 | Myomo wins on myoelectric powered arm braces. Kandu wins on noninvasive BCI therapy. |
| Lifeward | ReWalk personal exoskeleton and AlterG anti-gravity systems10 | Medicare fee of $91,032 for a personal exoskeleton9 | Individual users through Medicare and insurers; AlterG in more than 4,000 facilities9 | Lifeward wins on walking exoskeletons. Kandu wins on at-home BCI arm recovery. |
| Wandercraft | Atalante X and Eve self-balancing exoskeletons17 | Not published17 | Devices in more than 700 rehabilitation centers after buying Ekso18 | Wandercraft wins on self-balancing walking exoskeletons. Kandu wins on BCI hand therapy. |
| Vivistim | Vivistim paired vagus nerve stimulation for stroke rehab14 | Implantable therapy sold through clinical channels14 | Stroke rehab clinics offering VNS therapy14 | Vivistim wins on implanted VNS. Kandu wins on noninvasive at-home BCI. |
Limits
Patient pricing depends on clinical pathways and reimbursement, not a public cart price.1
The merged company is still integrating device and services businesses.2
Revenue is not disclosed. LeadIQ estimates about $10 million to $25 million annually for Kandu. This is an estimate, not a reported figure.5
What customers say
Where it helps
Chronic stroke patients past the usual rehab window are the primary IpsiHand fit.1
Health systems that want device plus remote care should evaluate the full Kandu offering.2
Where it falls short
Buyers seeking powered braces or walking exoskeletons should look at Myomo or Lifeward.
Leadership

Leo Petrossian
CEODr. Petrossian led Neurolutions and became CEO of Kandu after the April 2025 merger with Kandu Health.4,2
Sources
- Neurolutions, Homepage, accessed November 6, 2026
- Neurolutions, Kandu Health and Neurolutions merge, accessed November 6, 2026
- Kandu, Homepage, accessed November 6, 2026
- Kandu, Leo Petrossian, accessed November 6, 2026
- LeadIQ, Kandu company overview, accessed November 6, 2026, accessed November 6, 2026
- Myomo, About Myomo, accessed November 1, 2026
- Myomo, CMS posts final Medicare DMEPOS fee schedule rate for the MyoPro, March 1, 2024, accessed October 31, 2026
- Myomo, Second quarter 2026 results, SEC exhibit 99.1, August 5, 2026, accessed October 31, 2026
- Lifeward, Form 10-Q for the quarter ended September 30, 2024, accessed November 1, 2026
- Lifeward, Fourth quarter and full year 2025 financial results, accessed November 1, 2026
- Wandercraft, Atalante X, accessed November 1, 2026
- Wandercraft, Eve personal exoskeleton, accessed November 1, 2026
- Wandercraft, Wandercraft acquires Ekso Bionics, accessed November 1, 2026
- Vivistim, Homepage, accessed November 6, 2026
- Myomo, Homepage, accessed October 31, 2026
- Myomo, Fourth quarter and full year 2025 results, accessed October 31, 2026
- Wandercraft, Homepage, accessed November 2, 2026
- IZON, Wandercraft acquires Ekso Bionics to form major exoskeleton player, accessed November 2, 2026

